For example PARP inhibitors were demonstrated to be synthetic lethal in vitro with mutations in the tumor suppressors BRCA1 and BRCA2 (Farmer et al., 2005; McCabe et al., 2005) and clinical testing has established the same genetic dependence on tumor sensitivity to the PARP inhibitor olaparib in patients (Fong et al., 2009). Here, BRCA1 is linked to neoplasm.